Back to top
more

Thermo Fisher Scientific (TMO)

(Delayed Data from NYSE)

$454.74 USD

454.74
1,490,141

+5.80 (1.29%)

Updated Aug 7, 2025 04:00 PM ET

After-Market: $454.82 +0.08 (0.02%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value D Growth B Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 40% (147 out of 246)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Thermo Fisher Scientific is a scientific instrument maker and a world leader in serving science. In Nov 2006, Thermo Fisher Scientific, Inc. was formed through the merger of Thermo Electron Corporation with Fisher Scientific International Inc. On Feb 3, 2014, Thermo Fisher acquired Life Technologies Corporation. Following the acquisition, the new reporting segments are: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services.

Zacks Equity Research

Intersect ENT (XENT) Q2 Loss Widens, Revenues Beat Estimates

by Zacks Equity Research

Although Intersect ENT's (XENT) Q2 sales are down year over year, it's stronger than expected, led by the return of sinus surgery procedures using PROPEL.

Zacks Equity Research

Haemonetics (HAE) Q1 Earnings Beat Estimates, Margins Down

by Zacks Equity Research

Haemonetics' (HAE) first-quarter fiscal 2021 results reflect impressive performance by Blood Center segment despite dismal overall performance during the coronavirus-led crisis.

Zacks Equity Research

Fresenius Medical (FMS) Q2 Earnings & Revenues Top Estimates

by Zacks Equity Research

Fresenius Medical's (FMS) second-quarter earnings benefit from strong segmental performance.

Zacks Equity Research

AmerisourceBergen (ABC) Q3 Earnings & Revenues Top Estimates

by Zacks Equity Research

AmerisourceBergen's (ABC) fiscal third-quarter earnings benefit from segmental growth.

Zacks Equity Research

Patterson Cos. (PDCO) Hits 52-Week High, Can the Run Continue?

by Zacks Equity Research

Patterson Cos. (PDCO) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Zacks Equity Research

Luminex (LMNX) Q2 Earnings Beat Estimates, Revenues Miss

by Zacks Equity Research

Luminex (LMNX) witnessed total sample-to-answer molecular diagnostics revenue growth in Q2

Zacks Equity Research

Inogen's (INGN) Q2 Earnings Beat Estimates, Revenues Miss

by Zacks Equity Research

Inogen (INGN) saw growth in revenues within its Rental segment in Q2.

Zacks Equity Research

QIAGEN (QGEN) Q2 Earnings In Line With Estimates, Margins Up

by Zacks Equity Research

QIAGEN (QGEN) registered robust revenue growth across majority of geographies and both operating segments in Q2 despite the coronavirus-led economic crisis.

Zacks Equity Research

Zimmer Biomet's (ZBH) Q2 Earnings Beat, Margins Contract

by Zacks Equity Research

Zimmer Biomet's (ZBH) second-quarter elective procedure volumes decline across all regions.

Urmimala Biswas headshot

3 Medical Product Stocks Set to Beat This Earnings Season

by Urmimala Biswas

Here we discuss three medical product stocks that are due to report soon and are likely to beat estimates on earnings, riding on a host of factors.

Zacks Equity Research

Bruker (BRKR) Q2 Earnings Surpass Estimates, Margins Fall

by Zacks Equity Research

Bruker's (BRKR) second-quarter 2020 results reflect dismal performance by all segments and geographies due to coronavirus-led business disruptions.

Zacks Equity Research

Henry Schein (HSIC) Q2 Earnings Top Estimates, Margins Dip

by Zacks Equity Research

Henry Schein (HSIC) sees dismal segmental performance in Q2 due to disruptions resulting from the coronavirus pandemic.

Zacks Equity Research

STERIS' (STE) Earnings & Revenues Surpass Estimates in Q1

by Zacks Equity Research

STERIS' (STE) first-quarter fiscal 2021 results reflect strong performance by the Life Sciences segment despite the coronavirus-led economic crisis.

Zacks Equity Research

Pacific Biosciences (PACB) Posts Lower-Than-Expected Q2 Loss

by Zacks Equity Research

Pacific Biosciences (PACB) saw revenue decline in both its operating segments in Q2.

Zacks Equity Research

LabCorp (LH) Banks on Covance Amid Testing Volume Pressure

by Zacks Equity Research

LabCorp's (LH) COVID-19 related research too has been progressing well.

Zacks Equity Research

McKesson (MCK) Q1 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

McKesson's (MCK) fiscal first-quarter 2021 results benefit from strong U.S. Pharmaceutical and Specialty Solutions segment.

Zacks Equity Research

Hill-Rom's (HRC) Q3 Earnings Top Estimates, Margins Expand

by Zacks Equity Research

Hill-Rom (HRC) benefits from increased demand for critical care products due to the coronavirus outbreak.

Zacks Equity Research

Allscripts (MDRX) Q2 Earnings and Revenues Beat Estimates

by Zacks Equity Research

Allscripts (MDRX) witnessed decline in core Client Services and Software delivery unit revenues during Q2.

Zacks Equity Research

IDEXX (IDXX) Earnings Beat Estimates in Q2, Margins Rise

by Zacks Equity Research

IDEXX Laboratories (IDXX) registered strong contribution from its CAG business despite the pandemic-led challenges.

Zacks Equity Research

Teleflex (TFX) Beats Q2 Earnings Estimates, Margins Contract

by Zacks Equity Research

Teleflex (TFX) sales grow within the Americas attributable to Vascular Access and respiratory products, driven by COVID-19-led elevated demand.

Zacks Equity Research

DaVita (DVA) Earnings Beat Estimates in Q2, Revenues Miss

by Zacks Equity Research

DaVita's (DVA) dialysis services in the United States were solid in Q2.

Zacks Equity Research

Exact Sciences' (EXAS) Q2 Earnings Beat, Margin Declines

by Zacks Equity Research

Exact Sciences' (EXAS) legacy screening business sees a decline in revenues in Q2 earnings.

Zacks Equity Research

NextGen Healthcare (NXGN) Tops Q1 Earnings & Revenue Estimates

by Zacks Equity Research

NextGen (NXGN) benefited from its Recurring segment in Q1.

Zacks Equity Research

Bio-Rad (BIO) Q2 Earnings Beat Estimates, Gross Margin Rises

by Zacks Equity Research

Bio-Rad's (BIO) second-quarter 2020 results reflect strong performance by the Life Sciences segment, boosted by coronavirus-led increased testing demand.

Zacks Equity Research

Tandem Diabetes (TNDM) Q2 Earnings & Revenues Top Estimates

by Zacks Equity Research

Tandem Diabetes' (TNDM) strong domestic pump sales and pump shipments boosted the top line.